Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).
Aim(s): To assess response and outcome of PRRT with 177Lu-DOTATATE in PCC/PGL.
Materials and methods: Retrospective analysis of 22 patients with histopathologically confirmed PCC (n=9) & PGL (n=13), 2 localized/20 metastatic. Genetic testing in 13/22 patients showed 7 SDHx-related mutations, 2 NF-1 mutations and 4 were sporadic. Radiological response utilized RECIST 1.1 and toxicity was graded according to CTCAE4. Visual decrease (>50%) of tumor accumulation was considered as scintigraphic response. Reduction in plasma chromogranin A ≥50% was considered as biochemical response.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Prof. Anders Sundin
To read results and conclusion, please login ...
Further abstracts you may be interested in